Targeted therapies for Adrenocortical Carcinoma: IGF and beyond

Hormones and Cancer

Volumn 2, Issue 6, 2011, Pages 385-392

  Demeure, Michael J ^a   Bussey, Kimberly J ^a   Kirschner, Lawrence S ^b  

^a TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

Adrenocortical cancer; IGF1R; Targeted therapy; Tyrosine Kinase inhibitors

Indexed keywords

ANTINEOPLASTIC AGENT; BETA CATENIN; BEVACIZUMAB; BGJ 398; CISPLATIN; CIXUTUMUMAB; CWP 232291; DOVITINIB; DOXORUBICIN; ERLOTINIB; ETOPOSIDE; FP 1039; GEFITINIB; GEMCITABINE; LINSITINIB; MITOTANE; PACLITAXEL; PLERIXAFOR; PROTEIN INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; SCATTER FACTOR RECEPTOR; SOMATOMEDIN B; SOMATOMEDIN B RECEPTOR; SORAFENIB; SUNITINIB; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3; WNT PROTEIN; XL 184;

ADRENAL CORTEX CARCINOMA; ADRENAL CORTEX TUMOR; ADVANCED CANCER; ANTIANGIOGENIC THERAPY; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD BRAIN BARRIER; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER PATIENT; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG RESPONSE; GENE EXPRESSION; GENE MUTATION; HUMAN; HYPERGLYCEMIA; HYPERTENSION; MOLECULARLY TARGETED THERAPY; NONHUMAN; PERSONALIZED MEDICINE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIGNAL TRANSDUCTION; SOLID TUMOR; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; UNSPECIFIED SIDE EFFECT; UPREGULATION; WOUND HEALING IMPAIRMENT;

ADRENAL GLAND NEOPLASMS; ADRENOCORTICAL CARCINOMA; ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; INDIVIDUALIZED MEDICINE; INSULIN-LIKE GROWTH FACTOR II; MICE; MITOTANE; MOLECULAR TARGETED THERAPY; RECEPTOR, IGF TYPE 1; SMALL MOLECULE LIBRARIES; TUMOR MARKERS, BIOLOGICAL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 83555176247     PISSN: 18688497     EISSN: 18688500     Source Type: Journal    
DOI: 10.1007/s12672-011-0090-6     Document Type: Article

References (62)

1. Pollak M (2008) Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 8: 915-928.
2. Barlaskar FM, Spalding AC, Heaton JH et al (2009) Preclinical targeting of the type I insulin-like growth factor receptor in adrenocortical carcinoma. J Clin Endocrinol Metab 94: 204-212.
3. Imai K, Takaoka A (2006) Comparing antibody and small-molecule therapies for cancer. Nat Rev Cancer 6: 714-727.
4. Rodon J, DeSantos V, Ferry RJ, Kurzrock R (2008) Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: lessons from the first clinical trials. Mol Cancer Ther 7: 2575-2588.
5. Buck E, Eyzaguirre A, Rosenfeld-Franklin M et al (2008) Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors. Cancer Res 68: 8322-8332.
6. Boyd DB (2003) Insulin and cancer. Integr Cancer Ther 2: 315-329.
7. Dastrup E, Demeure MJ, Bussey KJ. Adrenocortical carcinoma cell lines are sensitive to compounds targeting the G2/M transition [abstract]. In Proceedings of the 101st Annual Meeting of the American Association for Cancer Research. Washington. AACR; 2010: Abstract nr 3672.
8. Baselga J, Swain SM (2009) Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 9: 463-475.
9. Kamio T, Shigematsu K, Sou H, Kawai K, Tsuchiyama H (1990) Immunohistochemical expression of epidermal growth factor receptors in human adrenocortical carcinoma. Hum Pathol 21: 277-282.
10. Sasano H, Suzuki T, Shizawa S, Kato K, Nagura H (1994) Transforming growth factor alpha, epidermal growth factor, and epidermal growth factor receptor expression in normal and diseased human adrenal cortex by immunohistochemistry and in situ hybridization. Mod Pathol 7: 741-746.
11. Samnotra V, Vassilopoulou-Sellin R, Fojo A et al (2007) A phase II trial of gefitinib monotherapy in patients with unresectable adrenocortical carcinoma (ACC). J Clin Oncol 25: 15527.
12. Quinkler M, Hahner S, Wortmann S et al (2008) Treatment of advanced adrenocortical carcinoma with erlotinib plus gemcitabine. J Clin Endocrinol Metab 93: 2057-2062.
13. de Fraipont F, El Atifi M, Cherradi N et al (2005) Gene expression profiling of human adrenocortical tumors using complementary deoxyribonucleic acid microarrays identifies several candidate genes as markers of malignancy. J Clin Endocrinol Metab 90: 1819-1829.
14. Giordano TJ, Thomas DG, Kuick R et al (2003) Distinct transcriptional profiles of adrenocortical tumors uncovered by DNA microarray analysis. Am J Pathol 162: 521-531.
15. Slater EP, Diehl SM, Langer P et al (2006) Analysis by cDNA microarrays of gene expression patterns of human adrenocortical tumors. Eur J Endocrinol 154: 587-598.
16. West AN, Neale GA, Pounds S et al (2007) Gene expression profiling of childhood adrenocortical tumors. Cancer Res 67: 600-608.
17. Turner N, Grose R (2010) Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer 10: 116-129.
18. Trudel S, Li ZH, Wei E et al (2005) CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4; 14) multiple myeloma. Blood 105: 2941-2948.
19. Xin X, Abrams TJ, Hollenbach PW et al (2006) CHIR-258 is efficacious in a newly developed fibroblast growth factor receptor 3-expressing orthotopic multiple myeloma model in mice. Clin Cancer Res 12: 4908-4915.
20. Chase A, Grand FH, Cross NC (2007) Activity of TKI258 against primary cells and cell lines with FGFR1 fusion genes associated with the 8p11 myeloproliferative syndrome. Blood 110: 3729-3734.
21. Loilome W, Joshi AD, ap Rhys CM et al (2009) Glioblastoma cell growth is suppressed by disruption of fibroblast growth factor pathway signaling. J Neurooncol 94: 359-366.
22. Zhang H, Masuoka L, Baker K et al (2007) FP-1039 (FGFR1: Fc), A Soluble FGFR1 receptor antagonist, inhibits tumor growth and angiogenesis. In AACR-NCI-EORTC International Conference Molecular Targets and Cancer Therapeutics Discovery, Biology and Clinical Applications. San Francisco, CA.; 2007.
23. Tolcher A, Papadopoulos K, Agnew J et al (2009) Preliminary results of a phase 1 study of FP-1039 (FGFR1: Fc), a novel antagonist of multiple fibroblast growth factor (FGF) ligands, in patients with advanced malignancies. Mol Cancer Ther 8: A103.
24. Leach FS, Nicolaides NC, Papadopoulos N et al (1993) Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer. Cell 75: 1215-1225.
25. Fishel R, Lescoe MK, Rao MR et al (1993) The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell 75: 1027-1038.
26. Reya T, Clevers H (2005) Wnt signalling in stem cells and cancer. Nature 434: 843-850.
27. Tadjine M, Lampron A, Ouadi L, Bourdeau I (2008) Frequent mutations of beta-catenin gene in sporadic secreting adrenocortical adenomas. Clin Endocrinol (Oxf) 68: 264-270.
28. Gaujoux S, Tissier F, Groussin L et al (2008) Wnt/beta-catenin and 3′, 5′-cyclic adenosine 5′-monophosphate/protein kinase A signaling pathways alterations and somatic beta-catenin gene mutations in the progression of adrenocortical tumors. J Clin Endocrinol Metab 93: 4135-4140.
29. Tissier F, Cavard C, Groussin L et al (2005) Mutations of beta-catenin in adrenocortical tumors: activation of the Wnt signaling pathway is a frequent event in both benign and malignant adrenocortical tumors. Cancer Res 65: 7622-7627.
30. Seki M, Tanaka K, Kikuchi-Yanoshita R et al (1992) Loss of normal allele of the APC gene in an adrenocortical carcinoma from a patient with familial adenomatous polyposis. Hum Genet 89: 298-300.
31. de Reynies A, Assie G, Rickman DS et al (2009) Gene expression profiling reveals a new classification of adrenocortical tumors and identifies molecular predictors of malignancy and survival. J Clin Oncol 27: 1108-1115.
32. Curtin JC, Lorenzi MV (2010) Drug discovery approaches to target Wnt signaling in cancer stem cells. Oncotarget 1: 563-577.
33. Cha JY, Jung J-E, Lee K-H et al (2010) Anti-tumor activity of novel small molecule Wnt signaling inhibitor, CWP232291, in multiple myeloma. In 52nd American Society for Hematology Annual Meeting. Orlando, FL: 3038.
34. Garber K (2009) Drugging the Wnt pathway: problems and progress. J Natl Cancer Inst 101: 548-550.
35. Sierra JR, Cepero V, Giordano S (2010) Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy. Mol Cancer 9: 75.
36. Cunningham MP, Thomas H, Marks C et al (2008) Co-targeting the EGFR and IGF-IR with anti-EGFR monoclonal antibody ICR62 and the IGF-IR tyrosine kinase inhibitor NVP-AEW541 in colorectal cancer cells. Int J Oncol 33: 1107-1113.
37. Jin Q, Esteva FJ (2008) Cross-talk between the ErbB/HER family and the type I insulin-like growth factor receptor signaling pathway in breast cancer. J Mammary Gland Biol Neoplasia 13: 485-498.
38. Huang F, Greer A, Hurlburt W et al (2009) The mechanisms of differential sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with EGFR/HER2 inhibitors. Cancer Res 69: 161-170.
39. Takahari D, Yamada Y, Okita NT et al (2009) Relationships of insulin-like growth factor-1 receptor and epidermal growth factor receptor expression to clinical outcomes in patients with colorectal cancer. Oncology 76: 42-48.
40. Barnes CJ, Ohshiro K, Rayala SK, El-Naggar AK, Kumar R (2007) Insulin-like growth factor receptor as a therapeutic target in head and neck cancer. Clin Cancer Res 13: 4291-4299.
41. Folkman J (1975) Tumor angiogenesis: a possible control point in tumor growth. Ann Intern Med 82: 96-100.
42. Zetter BR (2008) The scientific contributions of M. Judah Folkman to cancer research. Nat Rev Cancer 8: 647-654.
43. Escorcia FE, Henke E, McDevitt MR et al (2010) Selective killing of tumor neovasculature paradoxically improves chemotherapy delivery to tumors. Cancer Res 70: 9277-9286.
44. Hurwitz H, Fehrenbacher L, Novotny W et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335-2342.
45. Bergers G, Hanahan D (2008) Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 8: 592-603.
46. D'Agostino RB (2011) Changing end points in breast-cancer drug approval-the Avastin story. N Engl J Med 365(2): e2.
47. Quinkler M, Kroiss M, Hahner S et al (2011) Sunitinib in refractory adrenocortical carcinoma: results of a phase II trial. Endocr Abstr (in press).
48. Shojaei F, Lee JH, Simmons BH et al (2010) HGF/c-Met acts as an alternative angiogenic pathway in sunitinib-resistant tumors. Cancer Res 70: 10090-10100.
49. Smith SC, Theodorescu D (2009) Learning therapeutic lessons from metastasis suppressor proteins. Nat Rev Cancer 9: 253-264.
50. Cook LM, Hurst DR, Welch DR (2011) Metastasis suppressors and the tumor microenvironment. Semin Cancer Biol 21: 113-122.
51. Hurst DR, Welch DR (2011) Metastasis suppressor genes at the interface between the environment and tumor cell growth. Int Rev Cell Mol Biol 286: 107-180.
52. Iiizumi M, Liu W, Pai SK, Furuta E, Watabe K (2008) Drug development against metastasis-related genes and their pathways: a rationale for cancer therapy. Biochim Biophys Acta 1786: 87-104.
53. Addadi Y, Moskovits N, Granot D et al (2010) p53 status in stromal fibroblasts modulates tumor growth in an SDF1-dependent manner. Cancer Res 70: 9650-9658.
54. Sidhu S, Martin E, Gicquel C et al (2005) Mutation and methylation analysis of TP53 in adrenal carcinogenesis. Eur J Surg Oncol 31: 549-554.
55. Ronchi CL, Sbiera S, Kraus L et al (2009) Expression of excision repair cross complementing group 1 and prognosis in adrenocortical carcinoma patients treated with platinum-based chemotherapy. Endocr Relat Cancer 16: 907-918.
56. Berruti A, Terzolo M, Sperone P et al (2005) Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial. Endocr Relat Cancer 12: 657-666.
57. Demeure MJ, Stephan E, Sinari S et al (2011) Preclinical investigation of nanoparticle albumin-bound paclitaxel as a potential treatment for adrenocortical cancer. Ann Surg (in press).
58. Fallo F, Pilon C, Barzon L et al (1998) Paclitaxel is an effective antiproliferative agent on the human NCI-H295 adrenocortical carcinoma cell line. Chemotherapy 44: 129-134.
59. Stephan EA, Chung TH, Grant CS et al (2008) Adrenocortical carcinoma survival rates correlated to genomic copy number variants. Mol Cancer Ther 7: 425-431.
60. Eelen G, Vanden Bempt I, Verlinden L et al (2008) Expression of the BRCA1-interacting protein Brip1/BACH1/FANCJ is driven by E2F and correlates with human breast cancer malignancy. Oncogene 27: 4233-4241.
61. Ye L, Santarpia L, Gagel RF (2010) The evolving field of tyrosine kinase inhibitors in the treatment of endocrine tumors. Endocr Rev 31: 578-599.
62. Chen HX, Cleck JN (2009) Adverse effects of anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol 6: 465-477.